Effects of hypertonic/hyperoncotic treatment after rat cortical vein occlusion.
OBJECTIVE
To examine the effects of hypertonic/hyperoncotic treatment on physiologic variables and regional cerebral blood flow and to test its neuroprotective efficiency in a model of permanent venous ischemia.


METHODS
Randomized prospective study.


METHODS
University research institute.


METHODS
Adult male Wistar rats, weighing 359 +/- 54 g (n = 38).


METHODS
Rats were subjected to photochemical occlusion of two adjacent cortical veins. A randomized infusion with vehicle (0.9% NaCl), 10% hydroxyethyl starch 200,000 (HES), or 7.5% saline plus 10% hydroxyethyl starch 200,000 (HHES) was started 30 mins after two-vein occlusion. Effects on physiologic variables and regional cerebral blood flow (assessed by laser Doppler flowmetry) were studied up to 120 mins after two-vein occlusion. Two days after occlusion, the brains were removed for histologic evaluation.


RESULTS
After occlusion, regional cerebral blood flow decreased by 50%, significantly in all groups (from 47.3 +/- 3 to 22.2 +/- 2.2 laser Doppler units). In the vehicle and HES groups, regional cerebral blood flow further decreased to 12.9 +/- 1.9 and 17.8 +/- 2.3 laser Doppler units, respectively. HHES improved regional cerebral blood flow significantly to 27.3 +/- 3.5 laser Doppler units, particularly by reducing no-flow/low-flow areas and reducing infarct size.


CONCLUSIONS
We found that HHES reduced infarct size as a consequence of an improved regional cerebral blood flow and reduced no-flow/low-flow areas in the tissue at risk in the two-vein occlusion model.
Heimann
A
A
Institute for Neurosurgical Pathophysiology, Johannes Gutenberg-University Mainz, Germany.
Takeshima
T
T
Alessandri
B
B
Noppens
R
R
Kempski
O
O
D000818:Animals; D002545:Brain Ischemia / Q000473:pathology*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects*; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D007038:Hypotonic Solutions / Q000494:pharmacology; D007262:Infusions, Intravenous; D008297:Male; D009994:Osmolar Concentration; D010952:Plasma Substitutes / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012462:Saline Solution, Hypertonic / Q000494:pharmacology
D006895:Hydroxyethyl Starch Derivatives; D007038:Hypotonic Solutions; D010952:Plasma Substitutes; D012462:Saline Solution, Hypertonic